

Regular Meeting of the

Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, September 17, 2020, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Minutes (Open) - Approved

Members Present

Ali Alkoraishi, MD
Amara Balakrishnan, MD
Hao Bui, BS, RPh
Xuan Cung, PharmD
Dang Huynh, PharmD, Director of Pharmacy and UM
Jimmy Lin, MD, Chair
Laurie Nakahira, DO, Chief Medical Officer
Peter Nguyen, DO
Jesse Parashar-Rokicki, MD
Narinder Singh, PharmD

Members Absent

Dolly Goel, MD

Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist
Tami Otomo, PharmD, Clinical Pharmacist
Jayne Giangreco, Manager, Administrative
Services

Others Present

Amy McCarty, PharmD

1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:09 pm. Roll call was taken and a quorum was established.

2. Public Comment

There were no public comments.

3. Meeting Minutes

The 2Q2020 P&T Committee Open meeting minutes were reviewed.

It was moved, seconded and the open minutes of the June 18, 2020 P&T meeting were unanimously approved.

Motion: Dr. Nguyen

Second: Dr. Alkoraishi

Ayes: Dr. Alkoraishi, Dr. Balakrishnan, Ms. Bui, Dr. Cung, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Nguyen, Dr. Parashar-Rokicki, Dr. Singh

Absent: Dr. Goel

4. Standing Agenda Items

a. Chief Medical Officer Health Plan Updates

Dr. Nakahira provided an update on the Plan's response to the two state of emergency orders for the wildfires and COVID-19. The Plan continues with outreach calls to our vulnerable population, which includes high-risk members and members over the age of 65 with comorbidities. The Plan also worked with Santa Clara County to ensure our vulnerable population is on the County's list for evacuation orders and power outages. The majority of SCFHP's staff continues to work from home, and it is anticipated this will continue until sometime in 2021, pending updates from the County and the state.

Dr. Nakahira continued with staff updates. She announced that Lucille Baxter is the new Manager of Quality and Health Education, Raman Singh is the new Case Management Director; and Dang Huynh accepted the position as Pharmacy and Utilization Management (UM) Director.

Dr. Nakahira provided an update on the Community Resource Center (CRC), which is projected to open in mid-October 2020. The CRC is located at North Capital and McKee. The CRC will offer health education classes. There will be some SCFHP staff working there. Members will be also be able to meet with Case Managers there if it is more convenient.

b. Medi-Cal Rx Update

Dr. Huynh presented an update on Medi-Cal Rx. Beginning January 1, 2021, the pharmacy benefit for Medi-Cal will be carved back into the state. Their claims processor will be Magellan. The Plan will continue to manage the clinical aspects of pharmacy adherence and providing disease and medication management. The call script was finalized and rolled out by the state, and Customer Service will receive training on how to answer member and provider questions. DHCS will be sending out 90 and 60 day notices before the transition. The Plan will be sending out the 30 day notice.

SCFHP will identify members who may require more assistance during this transition and will offer help with prescription transfers. This includes assisting members who receive mail order prescriptions from pharmacies outside of California to transition them to a pharmacy enrolled in Medi-Cal Rx. Members will need to take their new SCFHP ID card and their Medi-Cal Benefits Identification Card (BIC) to the pharmacy. Members can locate network pharmacies on the state's website. Dr. Huynh explained that if the state does not cover a medication that a member is currently taking, there will be a 180 day transition period for the member to continue getting that drug. The state will also honor active prior authorizations for up to one year; they are discussing the potential for extending those authorizations.

The Plan is updating all member and provider material with Medi-Cal Rx information. SCFHP will also be conducting additional provider and member communication. Training for providers is available on the Medi-Cal Rx website, and the Plan will be sending out a fax blast to providers to notify them of this training. Dr. Huynh explained that there are ongoing discussions to clarify coverage of certain items in the state's scope document. The Plan is evaluating care coordination strategies for items that may be partially carved out. SCFHP continues to work with plan partners and delegates to ensure that information from DHCS and Magellan is communicated in a timely manner.

c. Plan/Global Medi-Cal Drug Use Review (DUR)

Dr. Otomo stated that SCFHP participates in the state's Global Drug Use Review (DUR) Board quarterly meetings, then assesses DUR activities that need to be implemented at the plan. There were no actions for SCFHP from the last DUR meeting.

For the Plan's Drug Use Evaluation (DUE) program for 3rd quarter, the Plan targeted members who may have persistent asthma based on claims history and did not receive an asthma controller medication in a recent 12 month period. SCFHP will send out letters to impacted providers within our Cal MediConnect and Medi-Cal lines of business.

d. NCQA Member Portal Evaluation

Dr. Nguyen presented an overview of the NCQA Member Portal Evaluation, which is required by NCQA on an annual basis to ensure accuracy and quality of our website for our Cal MediConnect members. The 2020 analysis was just completed and the website met 100% of the NCQA criteria.

e. 2019 2nd and 3rd Quarter Report Emergency Supply Reports

i. 2019 2nd Quarter Report

Dr. Nguyen discussed the Emergency Prescription Access Report for 2Q2019, and there were no issues identified.

ii. 2019 3rd Quarter Report

Dr. Nguyen reviewed the results for 3Q2019. There was one issue identified regarding a member's prescription for cefpodoxime, which is a non-formulary drug. The member went to three different pharmacies to try to fill the prescription and did not receive the drug. The member was referred to Case Management for follow-up. To remedy this gap, SCFHP will implement a point-of-sale (POS) message on cefpodoxime informing pharmacies that cefdinir is our formulary alternative. Dr. Huynh stated the Plan will send out a fax blast to the pharmacy network reminding them that for our Medi-Cal patients, they can input an override to provide an emergency 3-day supply. Dr. Nguyen will provide an update on this case at the next meeting.

f. Appeals & Grievances Pharmacy Report

i. 2020 1st Quarter Report

ii. 2020 2nd Quarter Report

Dr. Huynh presented the Appeals & Grievances Pharmacy Reports on behalf of Ms. Luong. Data and descriptions in slide deck required additional clarification. Dr. Huynh stated that he would validate the information with the G&A team and send out the updated slides or provide an update at the next meeting.

Dr. Lin inquired if appeals are mainly submitted by members or providers, and Dr. Huynh replied that the majority of appeals are submitted by providers.

Adjourned to Closed Session at 6:38 p.m.

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

5. Closed Meeting Minutes

The 2Q2020 P&T Committee Closed meeting minutes were reviewed.

It was moved, seconded and the closed minutes of the June 18, 2020 P&T meeting were **unanimously approved**.

6. Metrics and Financial Updates

a. Membership Report

Dr. Nakahira presented the Plan's membership.

b. Pharmacy Dashboard

Dr. Otomo reviewed the Pharmacy Dashboard for April 2020 through August 2020.

c. Drug Utilization and Spend

Dr. McCarty presented the Drug Utilization and Spend.

7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect (CMC) Formulary & Coverage Determination Criteria

a. Pharmacy Benefit Manager 2Q2020 P&T Minutes

Dr. McCarty reviewed the Pharmacy Benefit Manager 2Q2020 P&T Minutes.

b. Pharmacy Benefit Manager 3Q2020 P&T Part D Actions

Dr. McCarty reviewed the Pharmacy Benefit Manager 3Q2020 P&T Part D Actions.

It was moved, seconded and the Pharmacy Benefit Manager 2Q2020 and 3Q2020 Part D Actions were **unanimously approved**.

8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal and Prior Authorization Criteria

a. Old Business/Follow-Up

i. Dapagliflozin combinations

Dr. Huynh provided a follow-up from the last meeting regarding adding Farxiga and its combinations.

b. Formulary Modifications

Dr. Otomo presented the formulary changes made since the June 2020 meeting to the Committee.

It was moved, seconded and the Medi-Cal Formulary Modifications were **unanimously approved**.

c. Fee-for-Service Contract Drug List Comparability

Dr. McCarty reviewed the Fee-for-Service Contract Drug List (CDL) Comparability for Medi-Cal.

It was moved, seconded and the Fee-for-Service Contract Drug List Comparability recommendations were **unanimously approved**.

d. Prior Authorization Criteria

i. New or Revised Criteria

1. Enablex – *revised*
2. Myrbetriq - *revised*
3. Retacrit - *revised*
4. Penlac - *revised*

ii. Annual Review

1. Brand Name – *no changes*
2. Compounded Medications – *no changes*
3. Duragesic – *no changes*
4. Emend – *no changes*
5. Enbrel – *no changes*
6. Humira – *no changes*
7. Insulin Pens – *no changes*
8. Nicotrol – *no changes*
9. Off-label – *no changes*
10. Opioid Safety Edits – *no changes*
11. Quantity Limit – *no changes*

- 12. Taltz – *no changes*
- 13. Trintellix – *no changes*
- 14. Xelpros – *no changes*
- 15. Zyvox – *no changes*

Dr. Nguyen reviewed the revised PA criteria.

It was moved, seconded and the Prior Authorization Criteria was **unanimously approved**.

9. New Drugs and Class Reviews

a. New and Expanded Indications

Dr. McCarty presented an overview of the following drugs with new and expanded indications: Taltz, Cosentyx, Lynparza, Rubraca, Crystvita, Ilaris.

It was moved, seconded and the New and Expanded Indications recommendations were **unanimously approved**.

b. Oriahnn (elagolix, estradiol, norethindrone) – Uterine fibroids

Dr. McCarty gave an overview of uterine fibroids and a new drug, Oriahnn.

It was moved, seconded and recommendation for Oriahnn was **unanimously approved**.

Reconvene in Open Session at 7:18 p.m.

10. Discussion Items

a. New and Generic Pipeline

Dr. McCarty reviewed the New and Generic Pipeline. She noted that the major drug of interest in 3Q2020 is ofatumumab (Kesimpta), which is for multiple sclerosis and can be self-administered. In 4Q2020, a drug of interest is roxadustat, an oral agent for the treatment of anemia in chronic kidney disease. In 1Q2021, a drug of interest is aducanumab, a monoclonal antibody treatment for early stage Alzheimer's disease, which would make it the first biologic for this condition.

Dr. McCarty stated that drugs of interest in the generic pipeline are Nexium packets for oral suspension and Kuvan powder for oral suspension and tablet. Dr. Lin inquired as to whether or not Oxytrol or Humalog Mix 75/25 have been released as generics. Dr. McCarty replied that neither are available as generic products yet.

11. Adjournment

The meeting adjourned at 7:25 p.m. The next P&T Committee meeting will be on Thursday, December 17, 2020.

Jimmy Lin, MD, Chair

Date